Commentary Australian chief medical officers have embarked on a campaign to rehabilitate the AstraZeneca vaccine as a suitable COVID-19 jab. The vaccine lost much of its reputational shine when it was disclosed in the media that there had been several deaths from blood clotting issues after vaccinations. The blood clotting issue involves thrombosis with thrombocytopenia syndrome (TTS). According to the Therapeutic Goods Administration, the total number of confirmed and probable TTS cases in Australia is currently at 83 out of 5.4 million doses. The campaigners point out that the risk of blood clotting is only one out of 250,000 AstraZeneca jabs, whereas blood clotting for women who take contraception is one out of 1,000. Professor Adam Taylor, director of the Clinical Anatomy Learning Centre at the Lancaster University, concluded that: With this in mind, it’s worth remembering that while there is a small risk of clotting in some individuals who take the …